Track What Biological Products Companies Are Up To: Special Research on Gilead, Halozyme, Heska, Idera, and Kite Pharma
NEW YORK, February 17, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Moments ago, Analysts Review released new research updates concerning several important developing situations including Gilead (NASDAQ: GILD), Halozyme (NASDAQ: HALO), Heska (NYSE: HSKA), Idera (NASDAQ: IDRA), and Kite Pharma (NASDAQ: KITE). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
To access our full PDF reports on a complementary basis, please visit the links below.
--
Today's update concerns the following companies:
============
Full PDF Download Links (you may have to copy and paste the following links into your browser):
GILD Research Report: ( http://get.analystsreview.com/pdf/?c=Gilead&d=17-Feb-2015&s=GILD ),
HALO Research Report: ( http://get.analystsreview.com/pdf/?c=Halozyme&d=17-Feb-2015&s=HALO ),
HSKA Research Report: ( http://get.analystsreview.com/pdf/?c=Heska&d=17-Feb-2015&s=HSKA ),
IDRA Research Report: ( http://get.analystsreview.com/pdf/?c=Idera&d=17-Feb-2015&s=IDRA ),
KITE Research Report: ( http://get.analystsreview.com/pdf/?c=Kite%20Pharma&d=17-Feb-2015&s=KITE ).
============
--
Analyst Update: Quarterly Results, Leadership Appointments, Agreements, and Public Offerings
Reviewed by: Rohit Tuli, CFA®
The majority of the European markets closed lower on Monday, February 16, ahead of an announcement from the meeting of Eurozone finance ministers in Brussels. However, their discussion over a new financing arrangement for Greece broke down abruptly, showing a wide gap between Athens and its official creditors while also triggering a period of heightened uncertainty about Greece's future inside the currency bloc. The discussion ended after Greece rejected an extension of its current 240-billion-euro ($272 billion) bailout program under the conditions being offered by other ministers. The Euro Stoxx 50 decreased by 0.41 % to 3,433.30, the CAC 40 fell by 0.16 % to 4751.95 and the FTSE 100 was down by 0.24 % to 6857.05. However, the Asian markets ended higher on Monday. Japanese shares rallied to an eight-year high on Monday, on Greece deal hopes and after official data confirmed that Japan's economy pulled out of recession in the last quarter of last year. Chinese market also closed higher, after official data showed that China's foreign direct investment surged in January. US markets were closed on Monday on account of President's Day.
Gilead Sciences, Inc.'s (Gilead) Q4 2014 net income increased to $3.5 billion or $2.18 per diluted share from $791 million or $0.47 per diluted share during Q4 2013. Total revenues for the quarter stood at $7.3 billion, compared to $3.1 billion during Q4 2013. Total product sales for Q4 2014 were $7.2 billion, compared to $3.0 billion in Q4 2013.
Halozyme Therapeutics, Inc. (Halozyme) announced the appointment of Jean-Pierre Bizzari, M.D. to its Board of Directors. Dr. Bizzari had served Celgene Corporation as Group Head, Clinical Oncology Development since 2008. Prior to his role at Celgene, Dr. Bizzari was the Vice President Clinical Oncology Development for Sanofi-Aventis.
Heska Corporation (Heska) announced that it has signed a new distribution agreement with scil animal care company's Canadian unit (scil Canada) to market the Company's full line of hematology, blood gas & electrolytes and chemistry instruments and affiliated consumables, effective immediately.
Idera Pharmaceuticals, Inc. (Idera) announced plans to offer and sell up to $75 million shares of its common stock in an underwritten public offering. All of the shares in the offering would be sold by Idera, which plans to use the net proceeds to advance clinical development of certain of its programs.
Kite Pharma, Inc. (Kite Pharma) has appointed Salah D. Kivlighn, Ph.D., as Vice President, Marketing, and Anthony J. Polverino, Ph.D., as Vice President, Research, to help accelerate the Company's development of innovative cancer immunotherapy products.
--
About Analysts Review
At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.
--
Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article